fda warning letters glp-1 compounders september 2025 news Targets and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA cracks down on 'misleading'
Description
Cabou C, Campistron G, Marsollier N, et al
Women may tolerate slightly more than men
Combined with the Precision Peptide Genetic Test ($99 add-on after month one), this approach identifies whether you benefit more from sustained semaglutide monotherapy, dual-peptide combinations, or alternative GLP-1 compounds
We excluded articles about vessels other than coronary arteries
Patients with specific GIPR genotypes may tolerate compounded tirzepatide (which activates both pathways) better than semaglutide despite higher initial nausea expectations
